Finerenone attenuates myocardial apoptosis, metabolic disturbance and myocardial fibrosis in type 2 diabetes mellitus

BACKGROUND: Finerenone is a third-generation mineralocorticoid receptor antagonists, which has shown good cardiac function improvement in patients with type 2 diabetes in large-scale clinical trials. However, its specific role in diabetic cardiomyopathy remains unclear. We explored the potential fun...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Tao, Fu, Xiangrui, Liu, Ming, An, Fengshuang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10148405/
https://www.ncbi.nlm.nih.gov/pubmed/37120554
http://dx.doi.org/10.1186/s13098-023-01064-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10148405/
https://www.ncbi.nlm.nih.gov/pubmed/37120554
http://dx.doi.org/10.1186/s13098-023-01064-3

Ejemplares similares